Kivara Neurosciences was founded with a singular mission: to advance earlier detection of neurodegenerative disease through innovative molecular diagnostics — giving patients, families, physicians, and researchers the opportunity to act before irreversible neurological damage occurs.
Kivara Neurosciences was founded by siblings Robert Mons and Jenna Anderson, whose lives were forever changed by watching a parent develop a devastating neurodegenerative disease at a much younger age than anyone expected.
Their mother was diagnosed with Primary Progressive Aphasia (PPA), a rare form of frontotemporal neurodegeneration that gradually robbed her of her ability to communicate while preserving many other aspects of her awareness during the early stages of the disease.
For years, their family searched for answers. Like so many others facing neurodegenerative disease, they discovered that by the time symptoms become apparent, the underlying biological changes have often been developing silently for many years.
That realization became the foundation for Kivara Neurosciences.
“What if we could identify the earliest biological signals of disease before symptoms ever appear?”
Today, Kivara is dedicated to advancing blood-based molecular diagnostics designed to identify disease-associated biological changes earlier than has traditionally been possible, supporting future opportunities for earlier clinical evaluation, research participation, and precision medicine.
To advance next-generation molecular diagnostics that enable earlier detection of neurodegenerative disease through innovative biomarker discovery, artificial intelligence, and precision molecular science.
Our goal is to help shift healthcare from reacting to disease after symptoms appear to identifying biological changes earlier, when future interventions and research opportunities may have the greatest impact.
We envision a future in which neurodegenerative diseases are recognized and investigated at their earliest biological stages rather than after significant neurological decline has occurred.
Through scientific innovation, strategic collaborations, and rigorous clinical research, we aim to contribute to a future where earlier detection empowers better decision-making for patients, physicians, researchers, and families.
The values that shape every decision at Kivara — from the science we pursue to the partnerships we build.
Advancing technologies designed to identify disease-associated biological changes before clinical symptoms emerge.
Integrating molecular biomarkers, epigenetics, artificial intelligence, and precision diagnostics into one scalable platform.
Inspired by personal experience and driven by the desire to reduce the burden neurodegenerative disease places on future generations.
Working alongside academic institutions, clinicians, and research partners to advance the science of early detection.
The arc that connects who we are to the science we pursue and the future we hope to build.
The work at Kivara Neurosciences is driven by a simple belief:
Every family deserves the opportunity to know more, sooner.
While there is still much work ahead, we believe advances in molecular biology, biomarker discovery, and artificial intelligence have the potential to transform how neurodegenerative diseases are detected and studied.
Our commitment is to pursue that future through rigorous science, meaningful collaborations, and an unwavering focus on improving the lives of patients and families.
